Fcγ-Receptor IIIA Polymorphism p.158F Has No Negative Predictive Impact on Rituximab Therapy with and without Sequential Chemotherapy in CD20-Positive Posttransplant Lymphoproliferative Disorder

Table 3

Immunosuppression of patients treated in the PTLD-1 trial by FcγRIIIA p.158V/F polymorphism: non-F-carrier versus F carrier.

	FcγRIIIA p.158 non-F-carrier	FcγRIIIA p.158 F carrier	𝑃
Number of patients	8/16	8/16
Immunosuppression at diagnosis of PTLD, 𝑛/𝑁 (mean in mg, range in mg)
mTOR inhibitors	2/8 (2, 1–3)	1/8 (1)	n.s.
Calcineurin inhibitors	7/8	7/8	n.s.
Cyclosporin A	3/8 (193, 180–200)	2/8 (195, 190–200)	n.s.
FK506	4/8 (5, 2–9)	5/8 (6, 5–8)	n.s.
Antimetabolites	4/8	5/8	n.s.
Azathioprine	1/8 (75)	1/8 (75)	n.s.
MMF	3/8 (1333, 1000–2000)	4/8 (1625, 1000–2000)	n.s.
Steroids	6/8 (6, 4–10)	2/8 (13, 10–16)	0.05